BridgePoint Medical, Inc. (BridgePoint Medical), is planning to complete the clinical study entitled “CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study” for the product CrossBoss CTO Cathete by December 2009. The aim of the study is to determine if the product can facilitate safe and effective placement of a guidewire in the true lumen of coronary vessels distal to a chronic total occlusion (CTO).The trial is currently enrolling participants in Germany by invitation.
This treatment, open label, single group assignment, safety/efficacy study will enroll approximately 20 participants. The Principal Investigator is Horst Sievert, MD from CardioVascular Center Frankfurt, St. Katharinen Hospital.
CrossBoss CTO Catheter is designed for the placement of guidewires into discrete regions of the vasculature. It utilizes interventional techniques and requires no complicated hardware.